

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

VOLUNTARY ANNOUNCEMENT

PROPOSED ACQUISITION OF SHARES IN IMMUNOTECH BIOPHARM LTD

This is a voluntary announcement made by the board of directors (the “**Board**”) of China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”).

THE PROPOSED ACQUISITION

The Board is pleased to announce that, on 20 July 2021, Beijing Pharmaceutical Investment and Management (BVI) Limited (北京醫藥投資管理(BVI)有限公司), a wholly-owned subsidiary of the Company and as a purchaser (“**Purchaser**”), and Yue Cheng International Capital (HK) Limited, Hualida Development Co. Limited, Ren Xiaojuan (任小娟) and Bei Ni Ltd as sellers (collectively, the “**Sellers**”), amongst others, entered into a share purchase agreement (the “**Share Purchase Agreement**”), pursuant to which the Purchaser conditionally agreed to purchase, and the Sellers conditionally agreed to sell, an aggregate of 51,458,400 ordinary shares of Immunotech Biopharm Ltd (“**Immunotech**”) (representing 10.0% of the total issued share capital of Immunotech as of the date of this announcement) at a total consideration of approximately HK\$799.66 million, representing a price of HK\$15.54 per share (the “**Proposed Acquisition**”).

REASONS FOR AND BENEFITS OF THE PROPOSED ACQUISITION

Cellular immunotherapy is an important development direction for tumor therapy in the future. Through the Proposed Acquisition, it is expected that the Group can complete its strategic layout in the field of cellular immunotherapy. Immunotech together with its subsidiaries (“**Immunotech Group**”) has been deeply involved in the field of cellular immunotherapy for around 15 years, has established an experienced research and development team and full-scale technology platform, and has obtained the relevant intellectual property rights for its core technology and products.

INFORMATION OF THE PARTIES

The Group’s core business encompasses research and development, manufacturing, distribution and retail of an extensive range of pharmaceutical and other healthcare products.

Immunotech is a company incorporated in the Cayman Islands with limited liability and the shares of which are listed on the Main Board of The Stock Exchange of Hong Kong Limited (stock code: 6978.HK). Immunotech Group is a cellular immunotherapy biopharmaceutical company in China focusing on the research, development and commercialisation of T cell immunotherapy. To the best knowledge, information and belief of the directors of the Company (the “**Directors**”), and having made all reasonable enquiries, the Sellers and their respective ultimate beneficial owners are third parties independent of the Company and its connected persons.

IMPLICATIONS UNDER THE LISTING RULES

To the best knowledge, information and belief of the Directors, and having made all reasonable enquiries, the Proposed Acquisition and the transactions contemplated under the Share Purchase Agreement do not constitute a notifiable transaction under Chapter 14 nor a connected transaction under Chapter 14A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

This announcement is made by the Company on a voluntary basis to provide information to its shareholders and potential investors. **Shareholders and potential investors of the Company are reminded to exercise caution in dealing with the securities of the Company.**

By Order of the Board
China Resources Pharmaceutical Group Limited
Wang Chuncheng
Chairman

Hong Kong, 20 July 2021

As at the date of this announcement, the Board comprises Mr. Wang Chuncheng as chairman and non-executive Director, Mr. Han Yuewei, Mr. Li Xiangming and Mdm. Weng Jingwen as executive Directors, Mr. Yu Zhongliang, Mdm. Guo Wei, Mr. Hou Bo and Mr. Qing Mei Ping Cuo as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.